Natural human interferon alpha may act differently when given parenterally or orally to patients chronically infected with hepatitis B virus.
A literature review of patients chronically infected with hepatitis B virus (HBV) treated with natural human interferon alpha (nHuIFN-alpha) given parenterally every day for 28 days revelated that even the daily dose of (5 x 10(6)IU) of IFN-alpha inhibits cellular metabolism. As a result of metabolic block, the number of blood elements were diminished. Furthermore treated patients recorded several different adverse reactions. In contrast, among patients treated with the oral form of nHuIFN-alpha non metabolic block occurred and no adverse reactions were seen, even though the therapy lasted much longer. Two years after initiation of parenteral IFN-alpha therapy, the loss of HBV-BeAg was 53.8% and 28.8% of the patients had undergone seroconversion. In contrast, 77% of patients on oral interferon lost HBV-BeAg and 74% serconverted and normalized their biochemical liver function. The results suggest that the nHuIFN-alpha given orally and parenterally activate two different mechanisms responsible for virus elimination.
Georgiades
J A
JA
Georgiades Foundation for Therapy of Chronic Diseases, Stafford, TX 77477, USA.
D000284:Administration, Oral; D001772:Blood Cell Count; D002908:Chronic Disease / Q000188:drug therapy; D006509:Hepatitis B / Q000097:blood / Q000188:drug therapy*; D006513:Hepatitis B e Antigens / Q000097:blood; D006801:Humans; D007263:Infusions, Parenteral; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D008954:Models, Biological
D006513:Hepatitis B e Antigens; D016898:Interferon-alpha